Panacea Biotec Limited

NSEI:PANACEABIO Stock Report

Market Cap: ₹8.6b

Panacea Biotec Management

Management criteria checks 2/4

Panacea Biotec's CEO is Rajesh Jain, appointed in Feb 2002, has a tenure of 22.25 years. total yearly compensation is ₹8.24M, comprised of 72.8% salary and 27.2% bonuses, including company stock and options. directly owns 49.33% of the company’s shares, worth ₹4.23B. The average tenure of the management team and the board of directors is 9 years and 8.1 years respectively.

Key information

Rajesh Jain

Chief executive officer

₹8.2m

Total compensation

CEO salary percentage72.8%
CEO tenure22.3yrs
CEO ownership49.3%
Management average tenure9yrs
Board average tenure8.1yrs

Recent management updates

Why We Think Panacea Biotec Limited's (NSE:PANACEABIO) CEO Compensation Is Not Excessive At All

Sep 23
Why We Think Panacea Biotec Limited's (NSE:PANACEABIO) CEO Compensation Is Not Excessive At All

Recent updates

Why Investors Shouldn't Be Surprised By Panacea Biotec Limited's (NSE:PANACEABIO) Low P/S

Apr 04
Why Investors Shouldn't Be Surprised By Panacea Biotec Limited's (NSE:PANACEABIO) Low P/S

Why We Think Panacea Biotec Limited's (NSE:PANACEABIO) CEO Compensation Is Not Excessive At All

Sep 23
Why We Think Panacea Biotec Limited's (NSE:PANACEABIO) CEO Compensation Is Not Excessive At All

Estimating The Fair Value Of Panacea Biotec Limited (NSE:PANACEABIO)

Jul 28
Estimating The Fair Value Of Panacea Biotec Limited (NSE:PANACEABIO)

How Does Panacea Biotec's (NSE:PANACEABIO) CEO Pay Compare With Company Performance?

Feb 14
How Does Panacea Biotec's (NSE:PANACEABIO) CEO Pay Compare With Company Performance?

Introducing Panacea Biotec (NSE:PANACEABIO), A Stock That Climbed 80% In The Last Five Years

Jan 06
Introducing Panacea Biotec (NSE:PANACEABIO), A Stock That Climbed 80% In The Last Five Years

Is Panacea Biotec (NSE:PANACEABIO) Using Too Much Debt?

Sep 17
Is Panacea Biotec (NSE:PANACEABIO) Using Too Much Debt?

If You Had Bought Panacea Biotec (NSE:PANACEABIO) Stock A Year Ago, You Could Pocket A 78% Gain Today

Aug 03
If You Had Bought Panacea Biotec (NSE:PANACEABIO) Stock A Year Ago, You Could Pocket A 78% Gain Today

CEO Compensation Analysis

How has Rajesh Jain's remuneration changed compared to Panacea Biotec's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-₹117m

Sep 30 2023n/an/a

₹99m

Jun 30 2023n/an/a

₹334m

Mar 31 2023₹8m₹6m

-₹332m

Dec 31 2022n/an/a

₹12b

Sep 30 2022n/an/a

₹11b

Jun 30 2022n/an/a

₹11b

Mar 31 2022₹8m₹6m

₹11b

Dec 31 2021n/an/a

-₹2b

Sep 30 2021n/an/a

-₹2b

Jun 30 2021n/an/a

-₹2b

Mar 31 2021₹7m₹6m

-₹1b

Dec 31 2020n/an/a

-₹2b

Sep 30 2020n/an/a

-₹1b

Jun 30 2020n/an/a

-₹2b

Mar 31 2020₹8m₹6m

-₹2b

Dec 31 2019n/an/a

₹653m

Sep 30 2019n/an/a

₹715m

Jun 30 2019n/an/a

₹482m

Mar 31 2019₹7m₹6m

₹410m

Mar 31 2018₹7m₹6m

-₹716m

Compensation vs Market: Rajesh's total compensation ($USD98.77K) is above average for companies of similar size in the Indian market ($USD39.29K).

Compensation vs Earnings: Rajesh's compensation has increased whilst the company is unprofitable.


CEO

Rajesh Jain (59 yo)

22.3yrs

Tenure

₹8,240,000

Compensation

Dr. Rajesh Jain, Ph D has been Managing Director at Panacea Biotec Limited since March 12, 2018 and serves as its Whole-Time Director and serves as its Chairman of the Board at Panacea Biotec Limited since...


Leadership Team

NamePositionTenureCompensationOwnership
Rajesh Jain
Chairman of the Board & MD22.3yrs₹8.24m49.33%
₹ 4.2b
Sandeep Jain
Joint MD & Executive Director22.3yrs₹7.56m16.38%
₹ 1.4b
Devender Gupta
CFO & Head of Information Technology9yrs₹5.59mno data
Khalid Syed
Chief Scientific Officerno data₹6.26mno data
Vinod Goel
Group CFO9yrs₹6.78mno data
Ankesh Jain
Director of Sales & Marketing and Whole-Time Director8.1yrs₹2.93mno data
Parmanand Karan
Sr. Vice President - Business Development & Corporate Affairsno data₹5.08mno data
Rajneesh Chatrath
Vice President of Corporate Quality Assuranceno data₹6.00mno data
Lalitendu Mohanty
VP of Clinical Researchno data₹5.20mno data
Rajeeva Mangalum
Chief Operating Officer4.5yrsno datano data
Naresh Gupta
General Manager of Accounts & Taxationno datano datano data
Dinesh Singla
Senior Vice President of Pharma Research & Pharma Regulatory Affairs4.5yrsno datano data

9.0yrs

Average Tenure

56yo

Average Age

Experienced Management: PANACEABIO's management team is seasoned and experienced (9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Rajesh Jain
Chairman of the Board & MD39.5yrs₹8.24m49.33%
₹ 4.2b
Sandeep Jain
Joint MD & Executive Director39.5yrs₹7.56m16.38%
₹ 1.4b
Ankesh Jain
Director of Sales & Marketing and Whole-Time Director8.1yrs₹2.93mno data
Narotam Juneja
Additional Non-Executive Non-Independent Director2.1yrs₹200.00kno data
Manjula Upadhyay
Non-Executive Independent Director9.2yrs₹200.00kno data
Mukul Gupta
Non-Executive Independent Director8.1yrs₹200.00kno data
Ambika Sharma
Non-Executive Independent Directorless than a yearno datano data

8.1yrs

Average Tenure

62yo

Average Age

Experienced Board: PANACEABIO's board of directors are considered experienced (8.1 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.